Zelira Therapeutics

Zelira Therapeutics is a legitimate, ASX-listed biopharmaceutical company (ASX:ZLD) developing cannabinoid-based medicines for autism and insomnia. However, the submission quality is critically low, containing demonstrably false claims (e.g., 'most people have used my product', 'everyone' as audience) and using a market cap figure in the revenue field. While the project has real-world utility and regulatory progress (FDA milestones), its pre-revenue status, micro-cap valuation (~$7M AUD), and the unreliable nature of the submission heavily penalize the final score. The evaluation credits the verifiable regulatory achievements but penalizes the exaggerated reach and poor data integrity.